Navigation Links
Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
Date:5/21/2008

Leading Urologist Presents OrBIT Study Results Comparing Percutaneous Tibial Nerve Stimulation with Pharmaceutical Therapy at the 2008 American

Urological Association Annual Meeting

MINNEAPOLIS, May 21 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunction, today highlighted results from the OrBIT trial of its Urgent(R) PC System. The Urgent PC System is a proprietary, minimally invasive percutaneous tibial nerve stimulation (PTNS) device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence, symptoms often associated with overactive bladder (OAB). Dr. Kenneth M. Peters, Chairman of the Department of Urology at Beaumont Hospital in Royal Oak, Michigan, leads the OrBIT (OveRactive Bladder Innovative Therapy) multi-center trial and presented the comparative study's results today at the 2008 American Urological Association (AUA) Annual Meeting, being held in Orlando, Florida.

The results confirm that Urgent PC's PTNS reduces the incidence of voiding episodes at a rate comparable to tolterodine LA, known by the trade name Detrol(R) LA (Pfizer), the leading pharmaceutical therapy for OAB. Highlights from the study include:

-- 80% of PTNS patients considered themselves cured or improved, while 55%

of tolterodine LA patients considered themselves cured or improved.

-- Physicians considered 80% of PTNS patients cured or improved, compared

with 61% of tolterodine LA patients.

-- The frequency of voiding episodes was reduced in 73% of PTNS patients

versus 74% of tolterodine LA patients.

-- No serious adverse events were associated with either treatment. For

PTNS, 18.4% of patients reported at least one adverse event related to

treatment; 24.5% of patients in the tolterodine LA arm reported at

least one adverse event. Constipation and dry mouth were reported less

often in the PTNS arm compared to the tolterodine LA arm.

"PTNS provides comparable effectiveness to pharmaceuticals and may be considered an alternative to pharmacologic therapy for the treatment of OAB," Dr. Peters concluded.

In an oral presentation, "A Randomized Multi-center Study Comparing Percutaneous Tibial Nerve Stimulation with Pharmaceutical Therapy for the Treatment of Overactive Bladder," Dr. Peters presented results from a study of 100 patients conducted in 11 U.S. centers. These patients were randomized to either PTNS treatment with the Urgent PC, or to tolterodine LA. All patients in the study were diagnosed with urinary frequency at eight or more voids per day. Patients randomized into the PTNS treatment were treated weekly for 12 consecutive weeks, while patients randomized into the pharmacologic therapy were given a 90-day prescription for 4 mg daily. All patients completed voiding and bladder control diaries and questionnaires at baseline and after their 12-week follow-up.

"These results demonstrate that the Urgent PC is an effective and viable non-drug option for treating the urinary symptoms often associated with overactive bladder," said Dave Kaysen, President and Chief Executive Officer of Uroplasty, Inc. "Leading urologists across the country have been adding PTNS to their armamentarium for OAB treatment, reporting excellent outcomes and high patient satisfaction. We are delighted to have the OrBIT results validate Urgent PC's effectiveness compared to drugs and minimal side effects and expect that adoption will continue to improve, especially as additional clinical evidence emerges."

For more information about the Urgent(R) PC Neuromodulation System, please call 866-277-0466 or visit http://www.uroplasty.com.

About the Urgent PC Neuromodulation System

The Urgent PC neuromodulation system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of urge incontinence, urinary urgency and urinary frequency, symptoms often associated with overactive bladder. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to these symptoms. Uroplasty sells the Urgent PC system in the United States, Canada, and countries recognizing the CE mark. Outside of the United States, Urgent PC is also indicated for the treatment of fecal incontinence.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of urinary urgency, urinary frequency and urge incontinence, symptoms often associated with a diagnosis of overactive bladder (OAB). We also offer Macroplastique(R) Implants, an injectable, minimally invasive urethral bulking agent for the treatment of adult female stress urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, and Treasurer,

952.426.6140

EVC Group

Doug Sherk/Matt Selinger (Investors)

415.896.6820

Chris Gale (Media)

646.201.5431


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
4. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
5. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
6. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
7. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
8. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... GLENWOOD, Ill., Feb. 9, 2016  Landauer, Inc. (NYSE: ... environmental radiation measurement and monitoring, outsourced medical physics services ... results for its fiscal 2016 first quarter ended December ... --> Fiscal 2016 First Quarter Highlights , ... the first quarter of 2015 , Domestic Radiation Measurement ...
(Date:2/9/2016)...  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today ... and full year financial results on Tuesday, February 23, ... management will host a live audio webcast immediately following ... discuss fourth quarter and full year 2015 financial results ... for 2016 financial results. www.jazzpharmaceuticals.com .  Please ...
(Date:2/9/2016)... Amarantus BioScience Holdings, Inc. ... for Regenerative Medicine, Neurology and Orphan Diseases, today announced ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference ... New York City . The Company,s presentation ... 12:30 pm by Gerald E. Commissiong , President ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , is ... & Beverage and Dietary Supplement market segments across the western ... geographies east of the Rocky Mountains since 2012. Consistent performance in business ...
(Date:2/8/2016)... ... ... The Valentine’s Season is famous for gift giving with flowers, chocolates and other tokens of ... This year, for more than 5.6 million Americans suffering with Alzheimer’s, those store bought gifts ... them of the lives they’ve led and the people they’ve touched. , That’s ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling ... handle, you are not alone. According to the Center for Disease Control and Prevention ... type 2 diabetes and certain types of cancer, some of the leading causes of ...
(Date:2/8/2016)... ... 2016 , ... The Bell Agency, a full service insurance ... their ongoing community enrichment program. The current campaign fundraises for Angels & Doves, ... being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was founded in ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
Breaking Medicine News(10 mins):